CLINICAL TUMOR-MARKERS IN LUNG-CANCER

被引：90

作者：

NIKLINSKI, J

FURMAN, M

机构：

[1] Department of Thoracic Surgery, Medical School, Bialystok, 15 276

来源：

EUROPEAN JOURNAL OF CANCER PREVENTION | 1995年 / 4卷 / 02期

关键词：

DIAGNOSIS; LUNG CANCER; PROGNOSIS; TUMOR MARKERS;

D O I：

10.1097/00008469-199504000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Within the past few years, the measurement of serum and tissue markers has had an increasing influence on clinical decisions about initial treatment and follow-up. Lung cancer illustrates the types and importance of these various markers. This review presents data concerning the most studied and interesting markers in non-small cell (NSCLC) and small cell lung cancer (SCLC). CEA, TPA, SCC-Ag, CYFRA 21-1, ferritin, CA19-9, CA50, CA242, H-K-N-ras mutations and p53 mutation seem to be the most prolific in NSCLC, while NSE, BN/GRP, CK-BB, NCAM, IL-2R, IGF-I, transferrin, ANP, mAb (cluster 5), Le-y and c-N-L-myc mutation are markers in SCLC patients. Some of these serum markers might be useful adjuncts for monitoring response to therapy, including early detection of tumour reactivation to allow curative therapy and rapid detection of treatment failure to allow change of the regimen. The study of these markers also may lead to a better understanding of the biological characteristics of lung cancer. The information derived from these biological studies represents the most promising avenue towards new treatment strategies, as well as attempts at secondary prevention.

引用

页码：129 / 138

页数：10

共 114 条

[1]

Akoun G.M., Scarna H.M., Milleron B.J., Benichou M.P., Herman D.P., Scrum neuron-specific enolasc A marker for disease extent and response to therapy for small cell lung cancer, Chest, 87, pp. 39-43, (1985)

[2]

Anastasi A., Erspamcr V., Bucci M., Isolation and structure of bombesin and alytcsin, two analogous active peptides from the skin of the European frogs Bombina and Alyles, Expenentia, 27, pp. 166-167, (1971)

[3]

Aroncy R.S., Dcrmody W.C., Aldenderfer P., Et al., Multiple sequential biomarkers in monitoring patients with carcinoma of the lung, Cancer Treat Rep, 68, pp. 859-866, (1984)

[4]

Bergman B., Brczicka F.T., Fngstrom C.P., Larsson S., Clinical usefulness of scrum assays of neuron specific enolase, carcinocmbryonic antigen and CA 50 antigen in the diagnosis of lung cancer, Eur J Cancer, 29A, pp. 198-202, (1993)

[5]

Bliss D.P., Battey J.F., Lmnoila R.I., Birrer M.J., Gazdar A.F., Johnson B.E., Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines, J NCI, 82, pp. 305-310, (1990)

[6]

Bodcnimillcr I.I., Banauch D., Ofcnloch-Hanle B., Jaworek D., Dcssancr A., Technical and clinical evaluation ol a new assay lor NSCLC, the enzymum-test CYFRA 21-1, Proc Am Ass Cancer Res, 33, (1992)

[7]

Body J.J., Sculier J.P., Raymakres N., Et al., Evaluation ol squamous cell carcinoma antigen as a new marker for lung. Cancer, Cancer, 65, pp. 1552-1556, (1990)

[8]

Buccheri G.E., Violante B., Sartons A.M., Lerigno D., Cuncio A., Vola F., Clinical value of a multiple biomarker assay in patients wilh bronchogenic carcinoma, Cancer, 57, pp. 2389-2396, (1986)

[9]

Buccheri G.F., Ferrigno D., Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer, Chest, 93, pp. 565-570, (1988)

[10]

Buccheri G., Ferrigno D., Prognostic value of the tissue polypeptide antigen in lung cancer, Chest, 5, pp. 1287-1292, (1992)

← 1 2 3 4 5 6 7 8 9 10 →